Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
143.45
+2.86 (2.03%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 141.00 - 144.58
52 week 133.64 - 176.85
Open 141.50
Vol / Avg. 4.64M/5.13M
Mkt cap 108.42B
P/E 14.33
Div/yield 1.00/2.79
EPS 10.01
Shares 743.92M
Beta 1.14
Inst. own 80%
Jan 26, 2017
Q4 2016 Amgen Inc Earnings Release (Estimated) Add to calendar
Dec 7, 2016
Amgen Inc at Citi Global Healthcare Conference - Webcast
Nov 15, 2016
Amgen Inc Conference at American Heart Association Scientific Sessions 2016 - Webcast
Nov 8, 2016
Amgen Inc at Credit Suisse Healthcare Conference
Oct 27, 2016
Q3 2016 Amgen Inc Earnings Call - Webcast
Oct 27, 2016
Q3 2016 Amgen Inc Earnings Release
Sep 29, 2016
Arrowhead Pharmaceuticals Inc and Amgen Inc to Announce Two Cardiovascular Collaborations - Conference Call - Webcast
Sep 27, 2016
Amgen Inc Investor Conference Call to discuss CLARION Data - Webcast
Sep 19, 2016
Amgen Inc Conference Call to Discuss the results from the romosozumab phase 3 postmenopausal osteoporosis study (FRAME) - Webcast
Sep 16, 2016
Amgen Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 34.71% 32.03%
Operating margin 43.49% 39.10%
EBITD margin - 49.20%
Return on average assets 10.53% 9.88%
Return on average equity 26.57% 25.77%
Employees 17,900 -
CDP Score - 70 C

Address

1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 65
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 53
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 61
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 59
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 54
Bio & Compensation  - Reuters
Jonathan P. Graham Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Lori A. Johnston Senior Vice President - Human Resources
Age: 51
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 59
Bio & Compensation  - Reuters